UK markets close in 5 hours 47 minutes

Zymeworks Inc. (ZYME)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
6.12-0.18 (-2.86%)
At close: 04:00PM EDT
6.04 -0.08 (-1.31%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.30
Open6.30
Bid5.99 x 800
Ask0.00 x 800
Day's range6.06 - 6.32
52-week range4.56 - 39.41
Volume459,887
Avg. volume1,966,196
Market cap353.56M
Beta (5Y monthly)1.05
PE ratio (TTM)N/A
EPS (TTM)-4.97
Earnings date02 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.45
  • Business Wire

    Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

    VANCOUVER, British Columbia & SEATTLE, June 27, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology res

  • Business Wire

    Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company

    VANCOUVER, British Columbia & SEATTLE, June 10, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the "Board") has adopted a limited-duration shareholder rights plan (the "Rights Plan"). The Board adopted the Rights Plan in response to the unsolicited, non-binding proposal by All Blue Falcons FZE ("All Blue") to acquire Zymeworks and All Blue’s continued share accu

  • Business Wire

    Zymeworks Announces Participation in Upcoming Investor Conference

    VANCOUVER, British Columbia & SEATTLE, May 27, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: